AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates

After several market withdrawals, the FDA’s scrutiny around the PARP inhibitor class of cancer drugs doesn't seem to be abating.

The FDA plans to gather external experts for an advisory committee meeting to review AstraZeneca and Merck & Co.’s application for Lynparza in metastatic castration-resistant prostate cancer (mCRPC), the two companies said Thursday.